AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1384438 — intervention group
Group type: COMPARATOR
Intervention: Serenoa Repens
Number of subjects: 45
Study 6406586 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (acute phase)
Number of subjects: 10
Study 6406586 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (sustained phase)
Number of subjects: 10
Study 6406586 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (acute therapy)
Number of subjects: 10
Study 6406586 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (sustained therapy)
Number of subjects: 10
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release morphine as needed
Number of subjects: 536
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration of morphine
Number of subjects: 536
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrate baseline oxycodone
Number of subjects: 536
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise switch to morphine
Number of subjects: 536
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Add morphine on baseline oxycodone
Number of subjects: 536
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Add morphine on baseline fentanyl
Number of subjects: 536
Study 31201876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 536
Study 29385358 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 363
Study 29385358 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 363
Study 26774515 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially anxious participants (SAD and high socially anxious students)
Number of subjects: 0
Study 26774515 — intervention group
Group type: COMPARATOR
Intervention: Nonanxious participants
Number of subjects: 0
Study 26774515 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall gaze patterns
Number of subjects: 0
Study 24111929 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing oxygen (FIO2 28% and 35%)
Number of subjects: 29
Study 24111929 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 29
Study 24111929 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing oxygen (FIO2 35%)
Number of subjects: 29
Study 22580407 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario with greater utility for positive sequences
Number of subjects: 0
Study 22580407 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario with greater utility for negative sequences
Number of subjects: 0
Study 20111849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin‐A (Dysport 500‐1000U)
Number of subjects: 90
Study 20111849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18048467 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 36
Study 18048467 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 36
Study 15692475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (200 mg once weekly, 5 40‐mg tablets)
Number of subjects: 43
Study 15692475 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 43
Study 11792411 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH panel testing
Number of subjects: 32
Study 11792411 — intervention group
Group type: EXPERIMENTAL
Intervention: M-FISH
Number of subjects: 32
Study 11792411 — intervention group
Group type: COMPARATOR
Intervention: Standard cytogenetics
Number of subjects: 32
Study 11792411 — intervention group
Group type: COMPARATOR
Intervention: FISH panel test
Number of subjects: 32
Study 10649166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (1 g/kg body weight) for 2 consecutive days each month until 36 weeks' gestation
Number of subjects: 16
Study 10649166 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 consecutive days each month until 36 weeks' gestation
Number of subjects: 16
Study 9153784 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol administered orally at a dose of 10 mg/kg
Number of subjects: 5
Study 9153784 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol administered intravenously at a dose of 10 mg/kg
Number of subjects: 5
Study 9153784 — intervention group
Group type: COMPARATOR
Intervention: Comparison of methanol elimination kinetics between alcoholics and non-alcoholics
Number of subjects: 5
Study 9153784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraindividual variation in methanol elimination
Number of subjects: 5
Study 8475628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokinesia with daily fluid and salt supplements (water 26 ml/kg body weight and sodium chloride 0.16 g/kg body weight)
Number of subjects: 30
Study 8475628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokinesia (pure)
Number of subjects: 30
Study 8475628 — intervention group
Group type: COMPARATOR
Intervention: Long-distance running (control group)
Number of subjects: 30
Study 3895186 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid treatment (100 mg daily of betacarotene and canthaxanthine)
Number of subjects: 40
Study 3895186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxychloroquine treatment (200 mg daily)
Number of subjects: 40
Study 3895186 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 29244885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-curing resin cement (RelyX ARC, 3M ESPE)
Number of subjects: 80
Study 29244885 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive resin cement (RelyX U200, 3M ESPE)
Number of subjects: 80
Study 27614854 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 27614854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24622068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction of peripancreatic vessels
Number of subjects: 89
Study 24622068 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 89
Study 23420010 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (culture results reported as 'mixed growth')
Number of subjects: 81
Study 23420010 — intervention group
Group type: COMPARATOR
Intervention: Control group (culture results reported as usual)
Number of subjects: 81
Study 23420010 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 81
Study 23420010 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 20146387 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (vest)
Number of subjects: 0
Study 20146387 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter device (FD)
Number of subjects: 0
Study 20146387 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage
Number of subjects: 0
Study 20146387 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 17822705 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment group education programme
Number of subjects: 28
Study 17822705 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 28
Study 16884976 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (volatile anesthetic)
Number of subjects: 112
Study 16884976 — intervention group
Group type: COMPARATOR
Intervention: Propofol (intravenous anesthetic)
Number of subjects: 112
Study 12972520 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind 125 mg orally bid in combination with capecitabine 2,000 mg/m2 for 14 days in 21-day cycles
Number of subjects: 35
Study 12972520 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind 125 mg orally bid
Number of subjects: 35
Study 12972520 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 35
Study 10623702 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 522
Study 10623702 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 522
Study 8840343 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 30 mg/day
Number of subjects: 30
Study 8840343 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixole 1.5 mg/day
Number of subjects: 30
Study 8840343 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotiazepam 15 mg/day
Number of subjects: 30
Study 8840343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8840343 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of all agents
Number of subjects: 30
Study 1634784 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.1 mg/kg) followed by placebo (0.5 mg/kg as bolus and 0.5 mg/kg/hour infusion)
Number of subjects: 100
Study 1634784 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg/kg) followed by ketamine (0.5 mg/kg as bolus and 0.5 mg/kg/hour infusion)
Number of subjects: 100
Study 30424786 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1120360A (prolyl hydroxylase inhibitor)
Number of subjects: 0
Study 30424786 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat (clinical prolyl hydroxylase inhibitor)
Number of subjects: 0
Study 27548026 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 113
Study 27548026 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 113
Study 25448495 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) administered 1 hour before surgery
Number of subjects: 60
Study 22879399 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weightbearing (EWB) group (40 ankles)
Number of subjects: 81
Study 22879399 — intervention group
Group type: COMPARATOR
Intervention: Delayed weightbearing (DWB) group (41 ankles)
Number of subjects: 81
Study 19844694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg fish oil (FO) 1 day before LPS
Number of subjects: 3
Study 19844694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg fish oil (FO) 1 day before LPS
Number of subjects: 3
Study 19844694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg fish oil (FO) 2 hours before LPS
Number of subjects: 3
Study 19844694 — intervention group
Group type: COMPARATOR
Intervention: Control group from Pluess et al. trial
Number of subjects: 3
Study 18676544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Number of subjects: 104
Study 18676544 — intervention group
Group type: COMPARATOR
Intervention: No breakfast (Control)
Number of subjects: 104
Study 15878930 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 72
Study 15878930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15878930 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOAb (+) women
Number of subjects: 72
Study 15878930 — intervention group
Group type: COMPARATOR
Intervention: TPOAb (−) women
Number of subjects: 72
Study 14704377 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (case managers with risk and benefit information)
Number of subjects: 24
Study 14704377 — intervention group
Group type: COMPARATOR
Intervention: Control group (case managers with only patient assessments)
Number of subjects: 24
Study 10546917 — intervention group
Group type: EXPERIMENTAL
Intervention: LI160 (900 mg/d)
Number of subjects: 25
Study 10546917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8914412 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (fluticasone propionate; Flunase) and antiallergic medicine (azelastin) administered 4 weeks before pollen season (Group A)
Number of subjects: 25
Study 8914412 — intervention group
Group type: COMPARATOR
Intervention: Antiallergic medicine (azelastin) administered at the same time as Group A, with topical corticosteroid given after symptoms appeared (Group B)
Number of subjects: 25
Study 8914412 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (fluticasone propionate; Flunase) in Group A
Number of subjects: 25
Study 1854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.25 g/kg‐1 g/kg)
Number of subjects: 0
Study 1854375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery and adjuvant chemotherapy
Number of subjects: 22
Study 6587183 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 22
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated or bilateral thoracotomies
Number of subjects: 22
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge excision
Number of subjects: 22
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dn bloc resection of pericardium, chest wall, and diaphragm
Number of subjects: 22
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-free interval greater than 8 months
Number of subjects: 22
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray
Number of subjects: 22
Study 6587183 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 22
Study 30932047 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk genetic test result for obesity
Number of subjects: 223
Study 30932047 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected genetic test result for obesity
Number of subjects: 223
Study 30932047 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived genetic risk
Number of subjects: 223
Study 29504985 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation
Number of subjects: 40
Study 29504985 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 40
Study 26920949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide (300 mg/day) and rabeprazole (10 mg/day) combination therapy
Number of subjects: 81
Study 26920949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acotiamide (300 mg/day)
Number of subjects: 81
Study 24554392 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based CPAP follow-up (study 1)
Number of subjects: 90
Study 24554392 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference CPAP training (study 2)
Number of subjects: 90
Study 24554392 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face CPAP training (study 2)
Number of subjects: 90
Study 22721612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamate infusion
Number of subjects: 861
Study 22721612 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 861
Study 20585296 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate drink
Number of subjects: 18
Study 20585296 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 18
Study 16484110 — intervention group
Group type: EXPERIMENTAL
Intervention: False memories that imported perceived features
Number of subjects: 0
Study 16484110 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived details misattributed to false memories
Number of subjects: 0
Study 16484110 — intervention group
Group type: EXPERIMENTAL
Intervention: False memories of imagined objects
Number of subjects: 0
Study 14586388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine
Number of subjects: 8
Study 14586388 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked methamphetamine
Number of subjects: 8
Study 14586388 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methamphetamine
Number of subjects: 8
Study 11156742 — intervention group
Group type: EXPERIMENTAL
Intervention: Living food (LF) diet
Number of subjects: 0
Study 8785132 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotension using sodium nitroprusside, trimetaphan camsylate, or additional isoflurane
Number of subjects: 30
Study 8785132 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotension using trimetaphan camsylate
Number of subjects: 30
Study 8785132 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotension (all techniques)
Number of subjects: 30
Study 8785132 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotension for middle ear surgery
Number of subjects: 30
Study 1388181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection present
Number of subjects: 693
Study 1388181 — intervention group
Group type: COMPARATOR
Intervention: No dissection
Number of subjects: 693
Study 2856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 0
Study 30569083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg daily for 12 weeks
Number of subjects: 181
Study 30569083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 29286928 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 240
Study 29286928 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 240
Study 25459391 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m² plus cisplatin (70mg/m²) or carboplatin (AUC=5)
Number of subjects: 61
Study 25459391 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m² plus trastuzumab (8mg/kg loading dose, then 6 mg/kg every 21 days)
Number of subjects: 61
Study 25459391 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with cisplatin
Number of subjects: 61
Study 25459391 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with carboplatin
Number of subjects: 61
Study 25459391 — intervention group
Group type: COMPARATOR
Intervention: Control group (Arm A vs Arm B)
Number of subjects: 61
Study 23489705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod 400 mg, administered orally once a day for 90 days
Number of subjects: 18
Study 23489705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21076842 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise muscle ischemia (PEMI)
Number of subjects: 9
Study 21076842 — intervention group
Group type: COMPARATOR
Intervention: No PEMI (control trial)
Number of subjects: 9
Study 19189986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg kg(‐1)
Number of subjects: 30
Study 19189986 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study 17076456 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture plus standard emergency medical care
Number of subjects: 87
Study 17076456 — intervention group
Group type: COMPARATOR
Intervention: Standard emergency medical care
Number of subjects: 87
Study 17076456 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 87
Study 15639698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream QD for 12 weeks
Number of subjects: 847
Study 15639698 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream QD for 12 weeks
Number of subjects: 847
Study 12370877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression (P1, pain threshold; P2, averaged pain threshold and tolerance) with durations (T1, 30s; T2, 60s; T3, 90s)
Number of subjects: 119
Study 12370877 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic combinations (B1: hot pack plus active ROM; B2: B1 plus ischemic compression; B3: B2 plus TENS; B4: B1 plus stretch with spray; B5: B4 plus TENS; B6: B1 plus interferential current and myofascial release)
Number of subjects: 119
Study 9440585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparin
Number of subjects: 14
Study 9440585 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bonding
Number of subjects: 14
Study 8119037 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous shed blood
Number of subjects: 128
Study 8119037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall RC100 filter
Number of subjects: 128
Study 2504897 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day OKT3
Number of subjects: 68
Study 2504897 — intervention group
Group type: COMPARATOR
Intervention: 10-day OKT3
Number of subjects: 68
Study 1252342 — intervention group
Group type: EXPERIMENTAL
Intervention: High temperature crude coal tar
Number of subjects: 0
Study 1252342 — intervention group
Group type: COMPARATOR
Intervention: Low temperature crude coal tar
Number of subjects: 0
Study 1252342 — intervention group
Group type: COMPARATOR
Intervention: Standard refined tar
Number of subjects: 0
Study 31777236 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinqi Guiyuan needling (punctured with filiform needles for 30 min, three times per week for 4 weeks)
Number of subjects: 79
Study 31777236 — intervention group
Group type: COMPARATOR
Intervention: Estazolam (oral tablets once a day for 4 weeks)
Number of subjects: 79
Study 31777236 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinqi Guiyuan needling
Number of subjects: 79
Study 31777236 — intervention group
Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 79
Study 27130075 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment regimens (biphasic, aspart, detemir) in addition to metformin or placebo
Number of subjects: 412
Study 27130075 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during the first 3 months of the trial and subsequent dose of insulin
Number of subjects: 412
Study 25468411 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin capsules
Number of subjects: 24
Study 25468411 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study 23308016 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan, 100 mg (n=77)
Number of subjects: 153
Study 23308016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=76)
Number of subjects: 153
Study 21228732 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral supplementation of prebiotics (SC GOS/LC FOS/AOS)
Number of subjects: 113
Study 21228732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study 18097505 — intervention group
Group type: EXPERIMENTAL
Intervention: G. lucidum extract (6 mg once a day)
Number of subjects: 88
Study 18097505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 17038636 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA step 1 diet plus simvastatin (40 mg/d)
Number of subjects: 70